{"type":"trials","record":{"id":41689,"source_id":"clinicaltrials-gov","external_id":"NCT05381948","title":"Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)","brief_summary":"This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"EyePoint Pharmaceuticals, Inc.","enrollment":161,"countries":["United States"],"start_date":"2022-06-30","completion_date":"2024-04-24","last_update_date":"2025-10-15","source_url":"https://clinicaltrials.gov/study/NCT05381948","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"DAVIO2","age_range":"50 Years","comparator":"Aflibercept","organization":"EyePoint Pharmaceuticals, Inc.","interventions":["EYP-1901","Aflibercept 2mg/0.05mL Inj,Oph"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — Baseline (Day 1) an…","Change From Baseline in Best Corrected Visual Acuity up to Week 56 — Baseline (Day 1) and Weeks 32 and 56","Percentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56 — Baseline (Day 1) and W…","Percentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56 — Weeks 32 and 56","Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8 — From W…","Number of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose) — Weeks 32 and 56","Mean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT…","Change From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56 — Ba…","Percentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56 — Weeks 32 and…","Change From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56 — Baseline (Day 1) and Weeks 32…","Change From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56 — Baseline (Da…","Systemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56 — Up to Week 56","Ocular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32 — Up to Week 32","Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to W…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":true},"controlled_terms":["Wet Age-related Macular Degeneration","EYP-1901","Aflibercept 2mg/0.05mL Inj,Oph"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05381948","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-06-30 to 2024-04-24","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.854Z","intervention":["EYP-1901","Aflibercept 2mg/0.05mL Inj,Oph"],"participants":161,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — Baseline (Day 1) an…","Change From Baseline in Best Corrected Visual Acuity up to Week 56 — Baseline (Day 1) and Weeks 32 and 56","Percentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56 — Baseline (Day 1) and W…","Percentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56 — Weeks 32 and 56","Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8 — From W…","Number of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose) — Weeks 32 and 56","Mean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT…","Change From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56 — Ba…","Percentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56 — Weeks 32 and…","Change From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56 — Baseline (Day 1) and Weeks 32…","Change From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56 — Baseline (Da…","Systemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56 — Up to Week 56","Ocular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32 — Up to Week 32","Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to W…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41689","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}